Low serum long-acting natriuretic peptide level correlates with metabolic syndrome in hypertensive patients: A cross-sectional study

Archives of Medical Research

Volumn 44, Issue 3, 2013, Pages 215-220

  Hsieh, Jen Che ^a   Wang, Ji Hung ^a,b   Lee, Chung Jen ^c   Chen, Yu Chih ^a   Liou, Hung Hsiang ^d   Hsu, Bang Gee ^a,b  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c TZU CHI COLLEGE OF TECHNOLOGY   (Taiwan)

^d Hsin Jen Hospital   (Taiwan)

Author keywords

Hypertension; Long acting natriuretic peptide; Metabolic syndrome

Indexed keywords

INSULIN; LONG ACTING NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CARDIAC PATIENT; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREDICTOR VARIABLE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT;

AGED; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; FASTING; FEMALE; HUMANS; HYPERTENSION; INSULIN; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PEPTIDE FRAGMENTS; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 84876877458     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2013.03.001     Document Type: Article

References (26)

1. Vesely D.L. Which of the cardiac natriuretic peptides is most effective for the treatment of congestive heart failure, renal failure and cancer?. Clin Exp Pharmacol Physiol 2006, 33:169-176.
2. Vesely D.L. Atrial natriuretic peptides: anticancer agents. J Investig Med 2005, 53:360-365.
3. Beleigoli A.M., Diniz M.F., Ribeiro A.L. Natriuretic peptides: linking heart and adipose tissue in obesity and related conditions: a systematic review. Obes Rev 2009, 10:617-626.
4. Wang T.J., Larson M.G., Levy D., et al. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004, 109:594-600.
5. Wang T.J., Larson M.G., Keyes M.J., et al. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 2007, 115:1345-1353.
6. Tsai J.P., Liou H.H., Liu H.M., et al. Fasting serum fatty acid-binding protein 4 level positively correlates with metabolic syndrome in hemodialysis patients. Arch Med Res 2010, 41:536-540.
7. Hsu B.G., Shih M.H., Yang Y.C., et al. Fasting long-acting natriuretic peptide correlates inversely with metabolic syndrome in kidney transplantation patients. Transplant Proc 2012, 44:646-650.
8. Aigner E., Hinz C., Steiner K., et al. Iron stores, liver transaminase levels and metabolic risk in healthy teenagers. Eur J Clin Invest 2010, 40:155-163.
9. Narumi H., Yoshida K., Hashimoto N., et al. Increased subcutaneous fat accumulation has a protective role against subclinical atherosclerosis in asymptomatic subjects undergoing general health screening. Int J Cardiol 2009, 135:150-155.
10. Alberti K.G., Zimmet P.Z., Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006, 23:469-480.
11. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
12. Clerico A., Recchia F.A., Passino C., et al. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol 2006, 290:H17-H29.
13. Lafontan M., Moro C., Sengenes C., et al. An unsuspected metabolic role for atrial natriuretic peptides: the control of lipolysis, lipid mobilization, and systemic nonesterified fatty acids levels in humans. Arterioscler Thromb Vasc Biol 2005, 25:2032-2042.
14. Rubattu S., Sciarretta S., Ciavarella G.M., et al. Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass. J Hypertens 2007, 25:833-839.
15. Charloux A., Brandenberger G., Piquard F., et al. Dysregulation of pulsatility in aging IV. Pulsatile signaling and cardiovascular aging: functions and regulation of natriuretic peptide signaling. Ageing Res Rev 2008, 7:151-163.
16. Potter L.R. Natriuretic peptide metabolism, clearance and degradation. FEBS J 2011, 278:1808-1817.
17. Olsen M.H., Hansen T.W., Christensen M.K., et al. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 2005, 46:660-666.
18. Li W.Y., Chiu F.C., Chien Y.F., et al. Association of amino-terminal pro-brain natriuretic peptide with metabolic syndrome. Intern Med 2011, 50:1143-1147.
19. Bao Y., Shang X., Zhou L., et al. Relationship between N-terminal pro-B-type natriuretic peptide levels and metabolic syndrome. Arch Med Sci 2011, 7:247-256.
20. Nakatsuji H., Kishida K., Funahashi T., et al. Hyperinsulinemia correlates with low levels of plasma B-type natriuretic peptide in Japanese men irrespective of fat distribution. Cardiovasc Diabetol 2012, 11:22.
21. Moro C., Klimcakova E., Lolmède K., et al. Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue. Diabetologia 2007, 50:1038-1047.
22. Russell M.A., Morgan N. Expression and functional roles of guanylate cyclase isoforms in BRIN-BD11 β-cells. Islets 2010, 2:23-31.
23. You H., Laychock S.G. Long-term treatment with atrial natriuretic peptide inhibits ATP production and insulin secretion in rat pancreatic islets. Am J Physiol Endocrinol Metab 2011, 300:E435-E444.
24. Luchner A., Burnett J.C., Jougasaki M., et al. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol 1998, 32:1839-1844.
25. Teshima Y., Yufu K., Akioka H., et al. Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction. J Cardiol 2009, 53:58-64.
26. de Boer R.A., Martens F.M., Kuipers I., et al. The effects of the PPAR-gamma agonist pioglitazone on plasma concentrations of circulating vasoactive factors in type II diabetes mellitus. J Hum Hypertens 2010, 24:74-76.